Objective. This study is to define the statistical significance for detection of ESBL producers by the double disk synergy test and molecular test (Check-MDR CT 102 ), microdilution test (VITEK 2 with AES) and double disk synergy test (DDST), as well as the microdilution test and molecular test. Materials and methods. Phenotypic testing of 55 isolates Enterobacteriaceae (Escherichia coli (14/55), Klebsiella pneumoniae (34/55), Klebsiella oxytoca (3/55) and Proteus mirabilis (4/55) was performed by VITEK 2 Compact/AES. When this test showed positive results for the ESBL phenotype, then DDST with amoxicillin/clavulanate, ceftazidime, cefpodoxime, aztreonam, ceftriaxone and cefoxitin disks was performed along with Check-MDR CT 102 which identified CTX-M, TEM and SHV β-lactamases. Results. Applying the McNemar test, we determined that there was a statistically significant difference in the results of detection of ESBLs bacteria using DDST compared to molecular methods (95% CI=41.92 to 54.55; p<0.0001), as well as a DDST and VITEK 2/AES (95% CI=40.13 to 52.73; p<0.0001). We did not find any statistically significant difference in the results of detection of ESBL producers using molecular techniques and VI-TEK 2/AES (CI=-4,43 to 5,36; p=1). Also we did not find any statistical.. difference between the resistance to cefpodoxime and ceftriaxone (50/50) compared to the results of molecular tests. Conclusion. In routine daily testing, good detection of ESBLs bacteria, especially CTX-M can be obtained with phenotypic methods with VITEK 2/AES and by DDST with cefpodoxime, and ceftriaksone disks.
Introduction
Extended spectrum β lactamases (ESBL) are a group of enzymes which have the capability of hydrolyzing third-generation cephalosporins and aztreonam (but not cephamycins and carbapenems) and which are sensitive to inhibitors such as clavulanic acid, sulbactam and tazobactam. They developed from point mutation of genes which code production of primordial TEM-1, TEM-2, or SHV-1 β lactamases with replacement of the configuration of amino acids at an active site for these enzymes (1) . In 1989, Philippon, Labia and Jacoby presented the first example where resistance to β-lactam antibiotics mediated by β lactamases was a result of important changes in the spectrum of wells containing clavulanic acid and those which do not contain clavulanic acid indicates expression of an ESBL. The ESBL test, in combination with the VITEK 2 Advanced Expert System (AES), represents a very sensitive methodology for detection of ESBLs in clinical isolates. AES indicates possible inconsistent results in the antibiogram and, using existing knowledge about resistence mechanisms and CLSI standards, it indicates a phenotype for each isolate. Examples of phenotypes detected by AES are: ESBL, AmpC, carbapenemases (metallo or KPC β lactamases), as well as co-existing mechanisms of resistence (ESBL and AmpC) in the same isolate, where it may be necessary to apply molecular detection methods. The majority of VITEK 2 results are available on the same day that the VITEK 2 card is set up and VITEK 2 gives comments about the susceptibility test results, which can be used as guidelines by a clinician for antibiotic therapy.
Molecular diagnosis of ESBL is performed by the application of various methods, such as PFGE (pulsed field gel electrophoresis), multiplex PCR (polymerase chain reaction), sequencing of deoxyribonucleic acid (DNA) or pyrosequencing. One of the most sensitive methods, which is based on multiplex PCR and provides results in 24 hours, is the Check Points method. The principle of the Check Points diagnostic system is based on molecular recognition of the amplified target DNA sequence and subsequences with universal primers. The test uses highly-specific DNA markers necessary for differentiation of "real" ESBLs from non-ESBL variants TEM and SHV. This test detects and differentiates genes of different CTX-M families of enzymes, as well as SHV and TEM. Unlike conventional phenotypic methods, this test enables results to be obtained in one day.
Since results of genotypic testing methods are a reliable indicator of the existence substrates of these enzymes (2 (5, 6) . Using the disk diffusion method, a typical phenotypic profile of ESBLs shows resistance to third-generation cephalosporins (ceftazidime, cefpodoxime, ceftriaxone) and monobactams (aztreonam), an increase of the zone of inhibition for amoxicillin/clavulonate towards third-generation cephalosporins, and sensitivity to cefoxitin. Besides standard phenotypic methods, automated systems can also be used for the detection of resistance. VITEK 2 cards contain an ESBL test which monitors susceptibility of Escherichia coli and Klebsiella species to cefepime, ceftazidime and cefotaxime alone and in combination with clavulanic acid. The logarithmic reduction of growth within of genes for resistance due to the presence of ESBLs, this study aims to define statistical significance for detection of ESBL producers by the DDST and molecular test (Check-MDR CT 102 ), microdilution test (VITEK 2 with AES) and DDST, as well as microdilution test and molecular test. (7) respectively, and we used 20 mm disk spacing.
Material and methods
Klebsiella pneumoniae, Klebsiella oxytoca and Escherichia coli were considered resistant to cefpodoxime disks of 10 µg if the zone of inhibition was ≤17 mm, and ≤22 mm for Proteus mirabilis. Strains were considered resistant to: ceftazidime disks of 30 µg if the zone of inhibition was ≤22 mm, cefotaxime disks of 30 µg if the zone of inhibition was ≤27 mm, ceftriaxone disks of 30 µg if the zone of inhibition was ≤25 mm, aztreonam disks of 30 µg if the zone of inhibition was ≤27 mm (5) . We considered the screening test as positive if the zones of inhibition for the mentioned antibiotics were resistant, except for the zone of inhibition regarding cefoxitin, which was in the susceptible zone, i.e. ≥18 mm.
Genotyping of phenotypically confirmed ESBL isolates was performed with the multiplex PCR application of the commercially available Check-MDR CT102 (Check-Points Health BV) for detection of TEM, SHV and CTX-M genes according to the manufacturer's instructions. Before performing PCR, a DNA extraction from a pure culture of each isolate was made using the mini-kit QIAamp DNA (Qiagen, Sample & Assay Technologies).
Statistical analysis
The commercial statistical program Arcus Quickstat Biomedical was applied for data entry and basic statistical analysis. We used the chi-square test (McNemar) and statistical significance was tested at the 0.05 level. 
Results
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Results obtained by Check-MDR CT 102
50 out of 55 isolates tested by Check-MDR CT 102 were positive. In 49 isolates the group CTX-M1 beta-lactamases was identified and the group CTX-M9 was identified in the remaining one (Figure 3) .
Results obtained by the double-disk synergy test
All 55 isolates were tested by the double-disk synergy test. A typical phenotype profile of ESBL was found in 21 (38.18%). By considering the results of the molecular test Check-MDR CT 102 positive, we found a phenotypic profile in 21/50 (42%) isolates. Furthermore, we found 15 different phenotype profiles in the remaining isolates, 29/50 (58%) ( Table 1 ).
Out of 6 isolates which were positive (ESBL/ApmC) by the VITEK 2/AES, the phenotypic profile of AmpC beta-lactamases using DDST (when the diameter zone for ceftazidime, cefpotaxime, ceftriaxone or aztreonam was inside the zone of resistance, when there is no synergizing with clavulonic acid and when the organism is resistant to cefoxitin was found in 3 isolates) ( Table 2) .
Comparison of results obtained by double disk synergy test, Check-MDR CT102 and VITEK 2/AES
50 isolates tested by the molecular test were positive for genotype ESBL. Out of those, 21 were also positive by the double-disk synergy test. We found that the results of these two tests in detection of ESBL are significantly different (CI=41.92 to 54.55; p<0.0001). The sensitivity of double-disk synergy test was 48%. II combination 9/R 9/R 9/R 9/R 9/R 9/I III combination
AMC=amoxicillin/clavulanate; CAZ=ceftazidime; CPD= cefpodoxime; ATM=aztreonam; CRO=ceftriaxone; FOX= cefoxitin. Out of 50 isolates which tested positive for genotype ESBL by the molecular test, 48 were positive by the VITEK 2/AES. By applying the Chi˛ square test (McNemar) we found that the results of these two tests in detection of ESBL are not significantly different (95% CI=-4.43 to 5.36; p=1.0). The sensitivity of the VITEK 2/AES was 96%.
Out of 48 isolates which tested positive by the VITEK 2/AES, 21 were also positive by double-disk synergy test. By applying the Chi square test we found that these two tests are significantly different in detection of ESBL (95% CI=40.13 to 52.73; p<0.0001). The susceptibility of the test is 43% (Table3).
Sensitivity of ESBL isolates confirmed by molecular test on the cephalosporin's of III generation
50 isolates tested positive by molecular test. Out of those, 38 isolates were resistant to ceftazidime, 8 were intermediary susceptible and 4 were susceptible. All 50 isolates was resistant to ceftriaxon and cefpodoxime.
By applying the Chi square test, we found a statistically significant difference (95% CI=6.60 to 23.54, p=0.0034) between the results of the molecular test (where a positive result implies resistance to third-generation cephalosporins) and resistance to ceftazidime, whereas no statistical difference was found between the resistance to cefpodoxime and ceftriaxone (50/50) compared to the results of the molecular test (Figure 4) .
Resistance of ESBL isolates to amoxicilline/ clavulonate, aztreonam and cefoxitin confirmed by the molecular test
Considering 50 isolates confirmed by the molecular test, we applied the Chi square test and did not find a statistically significant difference between the results of the molecular test and resistance to amoksicillin/clavulonate (95% CI=-6.05 to 9.96; p=0.6875), and aztreonam (95% CI=-0.71 to 19.09; p=0.0654) but we found a statistically significant difference between the results of molecular test and cefoxitin (95% CI=23.46 to 41.73; p<0.0001) ( Table 4 ).
Discussion
The number of newly discovered ß -lactamases from Enterobacteriaceae has been rising annually, increasing the need for the introduction of new methods for their detection.
Many existing methods for detection of ESBL, AmpC or carbapenemases with Enterobacteriaceae and slow-fermentative Gram negative bacilli are technically demanding and their performance requires a great deal of time and special skills in a microbiologist. Small laboratories, which do not have appropriate equipment for molecular confirmation of individual types of resistance, must have a sensitive and specific method available for phenotypic detection of the same. According to the CLSI recommendations in M100-S21 Vol. 31 No. 1, phenotypic detection of ESBL by disk diffusion or broth dilution is based on the increased activity of cefotaxime or ceftazidime in the presence of clavulanic acid. Commercial methods, such as Etest, VITEK 2 and Phoenix, have developed phenotypic ESBL tests using CLSI methods as the reference comparative method. Molecular detection is based on the detection of resistance genes or Application of the disk diffusion method with ceftazidime, amoxicillin/clavulanate, and cefotaxime disks, which are placed 30 mm from the center of one to the center of another disk, was first described by Jarlier et al. in 1988. This method has remained a reliable method in clinical laboratories, although reading is sometimes difficult. The sensitivity of this test can be increased if disks are set at the distance of 30 mm and 20 mm (7) . In our study we used 20 mm disk spacing.
The sensitivity of a screening test for the detection of ESBLs with Enterobacteriaceae varies, depending on the antibiotic used as a predictor of their existence. Application of more than one antibiotic increases the sensitivity of the test. Cefpodoxime and ceftazidime show the greatest sensitivity for detection of ESBLs. Phenotypic confirmation tests do not detect all ESBLs. Besides ESBLs, some bacteria possess other β-lactamases which can mask detection of ESBLs during phenotypic testing, resulting in false-negatives. This includes AmpC β-lactamases and TEM β-lactamases resistant to inhibitors. Hyper production of TEM and SHV β-lactamases in bacteria with ESBLs can also give falsenegative results in phenotypic confirmation tests. This is why it is necessary to apply molecular detection methods to detect bacteria with the presence of multiple β-lactamases. However, molecular methods are not available in all laboratories (5) .
The susceptibility of double-disk synergy test in our research was 48%. 50 isolates tested by the molecular test were positive for genotype ESBL. Out of those, 21 were also positive by double-disk synergy test. We found that the results of these two tests in detection of ESBL are significantly different (95% CI=41.92 to 54.55; p<0.0001). In our study we found that DDST failed in AMC R isolates and we assume that narrowing the disk spacing might improve ESBL detection in AMC R isolates. The reason for these results is probably due to the joined resistance we found using VITEK 2/AES.
According to the recommendations of Livermore and Woodford from 2004, determining the susceptibility of isolated bacteria to ceftazidime and cefotaxime or to cefpodoxime should be the first line in detection of ESBLs. A confirmatory test should be done when resistance to any of the above mentioned antibiotics is found. To confirm the mechanism of resistance, it is very important to identify the organism to the species level, or at least for those isolates that are resistant to the above mentioned antibiotics. This is necessary because with Klebsiella pneumoniae and Escherichia coli, the cefpodoxime clavulanate combined disk is used as a confirmation test for the detection of ESBL, while with Enterobacter species and Citrobacter freundii, the cefpirome/clavulanate combination disk is used. According to the same author, the best choice of a cephalosporin is the one that can reveal all ESBLs, even when their production is rare, because since 2001, CTX-M enzymes, as well as TEM and SHV mutants, have been isolated in clinical and in outpatient specimens. For this reason, the best choice for detection of TEM and SHV ESBLs is resistance to ceftazidime and variable to cefotaxime, CTX-M ESBLs, are always resistant to cefotaxime and variable to ceftazidime and for all ESBLs resistance to cefpodoxime is compulsory (8). In our research, comparing disk diffusion and Check-MDR CT 102 , we defined that the best predictor for ESBLs is resistance to cefpodoxime and ceftriaxone, because in all 50 molecular test confirmed isolates we found resistance by the double disk synergy test, but also we found a statistically significant difference between the results of the molecular test and resistance to cefoxitin using disk diffusing testing (95% CI=23.46 to 41.73; p<0.0001). Out of 50 ESBL isolates confirmed by molecular tests, 28 isolates showed sensitivity to cefoxitin, 14 isolates had intermediate sensitivity and 8 isolates showed resistance. It was not a good predictor of ESBLs
Resistance to ceftazidime is used in practice to indicate the presence of an ESBL, and ceftazidime is the best substrate for TEM and SHV ESBLs. When ceftazidime is used alone in practice, then CTX-M producing isolates will not be detected, since they are susceptible to ceftazidime. Many ESBLs show an "inoculum effect" where MICs of broad-spectrum cephalosporins increase if the inoculum increases. To avoid the possibility of omission in the detection of the CTX-M enzymes, it is important to examine susceptibility to cefotaxime, besides the susceptibility to ceftazidime. Applying the double synergy test in our work, we found a typical phenotypic profile for ESBLs in 42% (21/50) of ESBL isolates which were confirmed by Check-MDR CT 102 . However, in 24% (12/50) of ESBL isolates we found that ceftazidime results were intermediate (8/50) or susceptible (4/50). Such findings can be explained by the fact that the ESBL isolates from our research belonged to the CTX-M genotype, for which ceftazidime zone diameters are intermediate or susceptible in in vitro conditions (9) .
In the study of Peer et al., (10), 10.8%, 9.5% and 5.4% of ESBL producing bacteria had false susceptibility to third-generation cephalosporins (ceftazidime, cefotaxime and ceftriaxone) with interpretation of a routine disk diffusion method. In our research, 4/50 isolates (8%), confirmed by the molecular method, had false susceptibility to ceftazidime and none of the isolates had false susceptibility to ceftriaxone using DDST and VITEK 2/AES. According to Peer et al. (10) , usage of more than one antibiotic, such as ceftazidime, cefotaxime, ceftriaxone, aztreonam and cefpodoxime, significantly improves the sensitivity of ESBL detection. The same authors underline that using DDST, (double-disk synergy test), PCDDTs (Phenotypic Confirmatory Disk Diffusion Tests) and cefoxitin for the screening of ESBL/AmpC beta-lactamases in positive Klebsiella isolates, resulted in ESBL detection for 69.5% (64/92) of the isolates, AmpC beta-lactamase detection in 19.5% (18/92) of the isolates, and detection of both mechanisms of resistance in 10.8% (10/92) of the isolates (10) .
Although specificity of DDST is well documented, its sensitivity is variable and varies between 76.5%, 93.3%, 87% and 79% in different studies. This difference in DDST sensitivity appears in different studies because standards set for performance of DDST are often complicated and very precise. Different DDST sensitivity also appears because of the application of different disks (11) .
In our research, out of 55 isolates examined with VITEK 2/AES (ESBL screening test includes the resistance on one of III generation cephalospofins) we found ESBL confirmation in 89.09% (49/55) of the isolates and in 10.9% (6/55) we found two phenotypes, AmpC and ESBL. However, after application of the molecular method Check-MDR CT 102 for ESBL detection, we obtained a positive result in 90.90% (50/55) isolates. With these isolates and using the double disk synergy test, we detected an ESBL phenotype in 42% (21/50) of the isolates. VITEK 2 /AES detected an ESBL/AmpC phenotype in 6 isolates and there was a phenotypic profile corresponding to the presence of AmpC β lactamases in 3/6 (50%) of the isolates by double disk synergy test.
In a multicenter evaluation of the VI-TEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance, Livermore et al. determined that for 126 of 137 reference genotypes there was a phenotypic match with the results obtained using the VITEK 2 Advanced Expert System; in 4 isolates there was a partial match, while in 6 isolates the results were discrepant. With 1 isolate the result could not be interpreted. The same study proved that discrepancies were found in only 64 of 963 interpretations in 10 European countries, which indicates that errors are minimal if the VITEK 2 and AES systems are used in an appropriate manner (12) . In our research, out of 50 isolates which tested positive for genotype ESBL by the molecular test, 48 were positive by the VITEK 2/AES. By applying the Chi square test, we found that the results of these two tests in detection of ESBL are not significantly different (p=1.0).The sensitivity of the VITEK 2/AES is 96%.
To analyze the sensitivity of the VITEK 2 ESBL test, in Spanu et al. (2006) , as well as our research, molecular ESBL identification was applied as a confirmation test and the sensitivity of the VITEK 2 ESBL test was found to be 98.1% (306/312). False positive results were found in 0.24% (2/817). In this research, out of the 50 positive results obtained by Check-MDR CT102, 48 were positive on the VITEK 2 Compact system and sensitivity was 96%. In 2 isolates which were positive by Check-MDR CT102, VITEK 2/ AES detected the AmpC/ESBL phenotype. In 5/55 isolates that were negative by Check-MDR CT102, the AmpC/ESBL phenotype (VITEK 2/AES) was found in 4/5 (80%). The ESBL phenotype was detected by VITEK 2/ AES in 1/5 (20%) of Check-MDR CT102 negative isolates. From our results and from results obtained by other authors, it can be concluded that VITEK 2 is a fast and reliable/practical tool for the routine identification of ESBL producing Enterobacteriaceae isolates (13) .
Limitations of study
During preparation of this work we had some limitations. One of them was the study's small sample size, which is a consequence of the inability to purchase a set of performance analysis of a large number of molecular tests, and the other was the domination of one ESBL type.
Conclusion
In conclusion, this study shows that in addition to molecular methods, which reliably detect genes for each individual mechanism of resistance in routine daily testing, good detection of ESBL-producing bacteria, especially CTX-M, can be obtained with phenotypic methods i.e. microdilution method in VITEK 2 Compact apparatus with AES and the disk diffusion test with a cefpodoxime, and ceftriaksone disk.
